Una D. McCann, M.D.
Professor
Associate Program Director JHBMC GCRC
Director, Anxiety Disorders Clinic
Main Office Address
Johns Hopkins Bayview Medical Center
5510 Nathan Shock Drive
Baltimore, MD 21224
Phone: 410-550-1972
Fax: 410-550-0030
E-mail: umccann@jhmi.edu
Off Campus Address
GCRC
Bayview B
Phone: 410-550-5038
Fax: 410-550-1227
Administrative Assistant
Rebecca Parvizomotlach
E-mail: rparviz1@jhmi.edu
Phone: 410-955-6792
Education and Government Service
1980 | B.A. | Princeton University |
1986 | M.D. | Duke University Medical School |
1984-1985 | Psychiatry Internship | Stanford University Medical School |
1985-1988 | Psychiatry Residency | Stanford University Medical School |
1987-1988 | Moos Clinical Research Fellowship | Stanford University Medical School |
1988-1999 | Government Service | United States Army and United States Public Health Service |
Professional Interests
My two active areas of research are in the areas of amphetamine-induced monoamine neurotoxicity (i.e., MDMA, Methamphetamine, ephedrine or amphetamine-induced monoaminergic neurotoxicity), and the neurobiology of anxiety disorders. Methods used in both research spheres include neuropharmacology, PET, MRI, fMRI, polysomnography, pharmacological challenge, and neuropsychiatric assessment. Studies of amphetamine neurotoxicity also include preclinical studies using microarrays, cell culture, rodents and primates.
Click here and here for Hopkins Brain Wise Newsletter articles about Dr. McCann's work
Selected Publications
McCann UD, Szabo Z, Scheffel U, Matthews WB, Dannals RF, Ravert HT, Musachio JL, Mertl MM, Ricaurte GA. Positron Emission Tomographic evidence of toxic effect of MDMA (AEcstasy@) on brain serotonin neurons in humans beings, The Lancet, 1998; 352:1433-1437.
McCann UD, Wong DF, Villemagne V, Dannals RF, Ricaurte GA. Brain dopamine neurotoxicity in abstinent methamphetamine and methcathinone users: Evidence from PET studies with [11C]WIN- 35,428, Journal of Neuroscience 1998;18(20):8417-8422.
McCann UD, Mertl MM, Eligulashvili V, Ricaurte GA. Cognitive performance in () 3,4- methylenedioxymethamphetamine (MDMA, "ecstasy") users: A controlled study, Psychopharmacology, 1999; 143:417-425
McCann UD, Slate SO, Geraci M, Roscow-Terrill D, and Uhde TW. A comparison of the effects of intravenous pentagastrin in patients with social phobia, panic disorder, and healthy volunteers, Neuropsychopharmacology, 1997;16(3):229-237.
Geraci M, Anderson TS, Slate-Cothren S, Post RM, McCann UD. Pentagastrin-induced sleep panic attacks: Panic in the absence of elevated baseline arousal. Biological Psychiatry, 2002;52(12):1183-9.
